Keimyung Med J.
2024 Dec;43(2):141-145. 10.46308/kmj.2024.00080.
Tocilizumab as a Potential Treatment Option for Severe Fever with Thrombocytopenia Syndrome
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Jeju National University, Jeju, Korea
- 2Department of Laboratory Medicine, College of Medicine, Jeju National University, Jeju, Korea
- KMID: 2562402
- DOI: http://doi.org/10.46308/kmj.2024.00080
Abstract
- Severe fever with thrombocytopenia syndrome (SFTS) is a viral hemorrhagic disease prevalent in Asian countries with a fatality rate of approximately 10% to 30%. However, there are currently no definitive treatments for reducing mortality. Variable management strategies have been attempted to reduce the mortality rate associated with SFTS. Tocilizumab is an inhibitor of interleukin-6 and is used to treat rheumatologic and viral infectious diseases. This article presents two cases of SFTS in older patients with neurological symptoms and explores the potential use of tocilizumab, as a treatment option. The patient showed improved consciousness and clinical outcomes after tocilizumab administration. This report describes this condition and reviews related literature.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Severe Fever with Thrombocytopenia Syndrome
- Strategies Against Severe Fever with Thrombocytopenia Syndrome Increasing in Korea
- Tocilizumab-induced Thrombocytopenia in Patients with Rheumatoid Arthritis
- The First Case of Non-retrospective Clinical Identification of Severe Fever with Thrombocytopenia Syndrome Patient in 2013 in South Korea
- Two Cases of Severe Fever with Thrombocytopenia Syndrome Manifested with Hemophagocytic Lymphohistiocytosis Successfully Treated with Steroids
